greeksoup/ stock research

Utah Medical Products Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 23 July 2026: press release. Guidance figures: 1 lowered, 1 narrowed. The quarter’s numbers.

Key takeaways

  • Second-quarter sales fell 14.3%: Consolidated 2Q 2026 sales were $8,529 thousand against $9,953 thousand a year earlier. First-half sales were $17,252 thousand, down 12.3%. Source
  • Two former customers drove the decline: Sales to the two former largest customers were zero in 2Q 2026. That loss accounted for 75% of the quarter's decline and 80% of the first-half decline. Source
  • New biopharma customers gained slowly: Sales to other biopharma new customers reached $211 thousand in 1H 2026. Management described this gain as slower than the company had expected. Source
  • Former customer sales set to zero: Management expects 2026 sales to PendoTECH and the former China distributor to be zero for the full year. Source
  • Half-year gross margin rose: Product mix improved as low-margin sales to the former China distributor ended. First-half gross profit was $10,040 thousand, down 9.8%. Source
  • Full-year litigation estimate raised: Management now estimates 2026 litigation expense below $1.6 million. The earlier view was a decline from the 2025 level of $1,355 thousand. Source
  • New-product output requires staffing: Ireland staffing kept for the former China distributor will be needed again for higher 2H 2026 production of new products. Source
  • Cash and investments reached $87.5 million: Cash and investments were $87,528 thousand at June 30, 2026, after 1H dividends of $1,976 thousand and buybacks of $206 thousand. The company has no debt. Source

“Unfortunately, in 1H 2026 the new sales did not develop as quickly as expected, so that the beginning plan for 2026 full year revenues is now unlikely.”

Utah Medical Products Inc., press release

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceFull year 2026sales decline of 10-13% compared to 2025Lowered from about the same as 2025 (10-K plan)
Litigation expense SourceFull year 2026less than $1.6 millionNarrowed from less than 2025 litigation expense of $1,355 thousand
Litigation expense Source2H 2026lower than 1H 2026

What changed from last quarter

  • Guidance lowered: The 2026 sales projection moved from about the same as 2025 to a 10-13% decline. Source
  • Guidance raised: The 2026 litigation estimate moved from less than 2025 to less than $1.6 million. Source
  • Ended: Femcare identifiable intangible asset amortization ended; the final UK expense was recorded in 1Q 2026. Source

Results and growth drivers

  • Second-quarter sales fell 14.3%: Consolidated 2Q 2026 sales were $8,529 thousand against $9,953 thousand a year earlier. First-half sales were $17,252 thousand, down 12.3%. Source
  • Two former customers drove the decline: Sales to the two former largest customers were zero in 2Q 2026. That loss accounted for 75% of the quarter's decline and 80% of the first-half decline. Source
  • New biopharma customers gained slowly: Sales to other biopharma new customers reached $211 thousand in 1H 2026. Management described this gain as slower than the company had expected. Source
  • Operating income down 17.1% in quarter: Operating income was $2,649 thousand in 2Q with a 31.1% operating margin. Litigation costs were $213 thousand higher than in 2Q 2025. Source
  • Net income fell 11.9% in quarter: Second-quarter net income was $2,686 thousand, 31.5% of sales. First-half net income was $5,290 thousand, down 13.1%. Source
  • Diluted EPS down 10.1% in quarter: Diluted EPS was $0.844 in 2Q and $1.661 in 1H, down 10.1% and 10.6%. Fewer diluted shares in 1H reduced the decline relative to net income. Source

Segments and regions

  • Domestic sales fell 11.9% in quarter: Domestic 2Q sales were $5,166 thousand. Non-PendoTECH OEM sales rose $166 thousand, while direct sales of other devices fell $406 thousand. Source
  • Outside-US sales fell 17.7%: OUS sales were $3,363 thousand in 2Q, $725 thousand lower. Remaining OUS sales to distributors rose $353 thousand, and 39% of OUS sales went direct to medical facilities. Source
  • Half-year OUS sales down 20.6%: First-half OUS sales totaled $6,525 thousand, down $1,690 thousand or 20.6%. Direct sales to medical facilities were 41% of OUS sales in 1H 2026. Source
  • Currency added little to sales: Exchange rates added $16 thousand to 2Q consolidated sales, about 0.2%. First-half currency added $185 thousand, or 1.1%. Source

“The lower OI was the result of 12% lower sales despite a higher GPM, together with $41 higher OE.”

Utah Medical Products Inc., press release

Products and customers

  • Filshie sales up in half-year: Domestic Filshie Clip System sales were $843 thousand in 2Q, $263 thousand lower after a high 1Q. First-half Filshie sales rose 10.7%. Source
  • Neonatal device sales declined: Domestic direct sales of other devices were $909 thousand lower in 1H. About 70% of that drop came from lower neonatal device sales. Source
  • Former customer sales set to zero: Management expects 2026 sales to PendoTECH and the former China distributor to be zero for the full year. Source

Costs and margins

  • Half-year gross margin rose: Product mix improved as low-margin sales to the former China distributor ended. First-half gross profit was $10,040 thousand, down 9.8%. Source
  • Quarterly margin dipped on overhead: Second-quarter margin slipped as Ireland shipments and staffing for the former China distributor and 2H new-product output kept costs in place. Ireland also supplies Filshie devices to all subsidiaries. Source
  • G&A fell in quarter, flat in half-year: 2Q G&A was $1,428 thousand, with the Femcare amortization gone. First-half G&A was $3,472 thousand, about level with 2025 despite $574 thousand less amortization. Source
  • Femcare amortization ended: Femcare identifiable intangible amortization was $531 thousand in 2Q 2025 and is now nil. The last UK expense was recorded in 1Q 2026. Source
  • Tax rate fell, lifting net income: The average tax provision rate was 18.3% in 2Q against 20.5%, and 18.2% in 1H against 20.9%. This reduced the decline in net income. Source
  • Non-operating income lower on rates: Net non-operating income was $637 thousand in 2Q, about flat. First-half net non-operating income was $1,254 thousand, down $91 thousand, from lower interest rates. Source

“The higher litigation expenses were due to a confluence of motions that won’t continue in 2H 2026.”

Utah Medical Products Inc., press release

Litigation and health costs

  • Litigation costs rose in half-year: Litigation expense was $213 thousand higher in 2Q and $341 thousand higher in 1H than a year earlier. Expert witness fees not previously estimated added to the 2Q figure. Source
  • Full-year litigation estimate raised: Management now estimates 2026 litigation expense below $1.6 million. The earlier view was a decline from the 2025 level of $1,355 thousand. Source
  • Health plan costs rose in U.S.: U.S. G&A self-insured health plan expenses were $135 thousand higher in 1H 2026. Other U.S. G&A rose $128 thousand, mainly from those plan costs. Source

Demand, inventory and receivables

  • Inventory built during lower sales: Inventories rose $1,068 thousand since year-end to $9,003 thousand. Average inventory turns fell to 1.7 from 2.0 in the last quarter of 2025. Source
  • Shipment timing drives quarterly swings: Distributors order larger quantities each time to limit transit and logistics costs, so shipment timing moves quarterly comparisons. Source
  • New-product output requires staffing: Ireland staffing kept for the former China distributor will be needed again for higher 2H 2026 production of new products. Source

Capital, cash and shareholder returns

  • Cash and investments reached $87.5 million: Cash and investments were $87,528 thousand at June 30, 2026, after 1H dividends of $1,976 thousand and buybacks of $206 thousand. The company has no debt. Source
  • Dividend held at $0.310 per share: Dividends were $987 thousand in 2Q at $0.310 per share, 37% of net income. First-half dividends totaled $1,976 thousand. Source
  • Buybacks slowed sharply in 1H: The company repurchased 3,403 shares in 1H for $206 thousand, against $6,709 thousand spent in 1H 2025. Source
  • Working capital lifted current ratio: The current ratio rose to 48.6 at June 30, 2026, from 37.6 at year-end. The company attributed this to favorable 1H working capital changes. Source

Coming up, as management said on 23 July 2026

  • 10-Q to add revenue detail: The 10-Q for 2Q 2026, to be filed in August, will give further revenue segmentation detail. Source

Figures management reported

FigureReported
Filshie Clip System domestic sales, 2Q 2026 Source$843 thousand
OUS sales direct to medical facilities, 2Q 2026 Source39% of OUS sales
Combined sales to two former customers, 1H 2026 Source$0 (vs $1,923 thousand in 1H 2025)

Risks management discussed

  • Demand: Slower gains from new biopharma customers mean recovery of former-customer sales is behind the original plan. Source
  • Regulatory: Litigation remains open in four of the nineteen cases, and legal work and expert costs continue to affect expense. Source
  • Operational: Factory overhead is largely fixed, so lower volume weighs on gross margin when those costs are not reduced. Source
  • Financial: U.S. self-insured health plan costs were $135 thousand higher in 1H, adding to G&A expense. Source

Earlier plans management reported on

  • Met: Zero sales to the two former customers in 2Q 2026 were consistent with the projection in the 10-K filed at the start of the year. Source
  • Delayed: Management said new product sales did not develop as quickly as expected in 1H 2026. Source
  • Met: Management said first-half gross margin was higher than in 2025 as expected, on a more favorable product mix. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.